/Companies

Eikonoklastes Therapeutics

Cincinnati, US · 2 known investors

Find your way into Eikonoklastes Therapeutics

Sign up to see every warm intro you have to Eikonoklastes Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Eikonoklastes Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Founders & leadership

BHBruce Halpryn
Bruce HalprynExecutive

Board

SL
Samuel LeeBoard directorInvestor at CincyTech
KMKenneth Morand
Kenneth MorandBoard directorLife Sciences Partner at CincyTech
TF
Thomas FinnBoard director
JN
Joseph NolanBoard director
RJ
Robert JohnsonBoard director

Investors · 2

Reported raises · per SEC filings

Form D private placements

$25M disclosed across 6 of 7 rounds · 2020–2025

▶$16.1MraisedOct 2026 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director
  • Samuel LeeExecutive Officer, Director
  • Kenneth MorandDirector
  • Thomas FinnDirector
  • Robert JohnsonDirector
  • Joseph NolanDirector
Offering amount
$18.6M
Amount sold
$16.1M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedJun 2024 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas FinnDirector
  • Neel PatelDirector
  • Meyer FrucherDirector
  • Kenneth MorandDirector
  • Bruce HalprynExecutive Officer, Director
  • Samuel LeeExecutive Officer, Director
Offering amount
$8M
Amount sold
$2.4M
First sale
Jun 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
  • Bruce HalprynExecutive Officer, Director
  • Thomas FinnDirector
  • Kenneth MorandDirector
  • Meyer FrucherDirector
Offering amount
$15M
Amount sold
$2M
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedJan 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director
  • Kenneth MorandDirector
  • Thomas FinnDirector
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
Offering amount
$7M
Amount sold
$2.8M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedMay 2021 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director, Promoter
  • Thomas FinnDirector
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
  • Kenneth MorandDirector
Offering amount
$7M
Amount sold
$3.2M
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedMar 2020 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • SAMUEL LEEExecutive Officer, Director, Promoter
  • BRUCE HALPRYNExecutive Officer, Director, Promoter
Offering amount
$4M
Amount sold
$1.1M
First sale
Feb 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Eikonoklastes Therapeutics's investors?
Eikonoklastes Therapeutics's investors include CincyTech, JobsOhio Ventures.
How much funding has Eikonoklastes Therapeutics raised?
Eikonoklastes Therapeutics has disclosed $25M raised across 6 of its 7 known rounds.
Where is Eikonoklastes Therapeutics headquartered?
Eikonoklastes Therapeutics is headquartered in Cincinnati, US.